Pfizer CEO Albert Bourla, during a press conference with the European Commission President, said that moving forward the pharmaceutical giant which has been centre stage in the fight against Covid-19 will be producing a redesigned vaccine specifically targeting the Omicron variant.
In a news report appearing in Reuters, Bourla further added the Covid-19 vaccine developed to combat the variant of the coronavirus will be the most likely scenario as cases from Omicron infection surge across the globe. He said Pfizer and partner BioNTech SE are working on both Omicron targeted vaccine variants as well a shot that would include both the previous vaccine as well as vaccines targetted at the new variant.
The group is already preparing to file for approval of the redesigned vaccine and could start producing it as soon as March.
Many nations are adopting booster shots to quell the rising infection rate of Covid-19, however as evident in countries like Isreal and parts of Europe, despite the shots cases don’t seem to come down. Although data shows that Omicrom leaves less severe symptoms but there is a worry about its effects on those with core morbidity.